In this article, John S. Summers and Dylan J. Steinberg discuss the US Supreme Court’s decision in Sorrell v. IMS Health, Inc., which addresses a core pharmaceutical marketing approach, exemplifies the court’s corporate speech jurisprudence, and provides a window into data privacy issues the court will face in upcoming terms.
This article was originally published in The Legal Intelligencer.
